Asthma Management

Indications and Contraindications

• Montelukast is recommended for the treatment of mild to moderate persistent asthma, exercise-induced bronchospasm, and allergic rhinitis by the American Academy of Allergy, Asthma, and Immunology 1
• Montelukast can be used in patients with temporomandibular disorder (TMD) when clinically indicated for asthma or allergic rhinitis, acting as a leukotriene receptor antagonist to reduce inflammation in the airways 1
• The European Respiratory Society suggests that corticosteroids are more effective than montelukast for asthma control and remain the first line of treatment 2
• For allergic rhinitis, corticosteroids or antihistamines can be effective alternatives to montelukast, as recommended by the European Academy of Allergy and Clinical Immunology 2

Safety and Monitoring

• Limited data suggest no significant increase in the risk of malformations with montelukast use in pregnant women, but the number of exposed women is insufficient to guarantee fetal safety, according to the European Respiratory Journal 3
• Cases of limb reduction defects have been reported with montelukast use during pregnancy, as reported by the European Respiratory Journal 3
• Montelukast can be used during pregnancy when conventional medications fail to control asthma, as recommended by the American College of Obstetricians and Gynecologists 3
• Patients with TMD and bruxism related to anxiety should be monitored closely for potential exacerbation of symptoms due to montelukast's neuropsychiatric effects, as suggested by the American Dental Association 1
• Patients with a history of sleep disorders should be monitored for potential worsening of TMD symptoms due to montelukast's effects on sleep, as recommended by the American Academy of Sleep Medicine 1

Special Considerations

• Montelukast can be prescribed for long-term control of persistent asthma symptoms in children, with no specific maximum duration limit established in guidelines, according to the American Academy of Allergy, Asthma, and Immunology 4
• Inhaled corticosteroids remain more effective than montelukast for controlling asthma symptoms in children, as recommended by the American College of Allergy, Asthma, and Immunology 4, 5, 6
• Montelukast does not appear to affect growth in children, unlike inhaled corticosteroids, as stated by the American Academy of Pediatrics 4
• Montelukast can be used as an alternative controller in mild persistent asthma when inhaled corticosteroids cannot be administered, as suggested by the National Asthma Education and Prevention Program 7
• Montelukast can be used as add-on therapy to inhaled corticosteroids in moderate persistent asthma, according to the Global Initiative for Asthma 7
• Montelukast is suitable for patients with coexisting allergic rhinitis and asthma, as recommended by the American Academy of Allergy, Asthma, and Immunology 8, 5
• Montelukast should not be used as monotherapy in moderate to severe persistent asthma, as stated by the American College of Allergy, Asthma, and Immunology 4
• Montelukast should be discontinued if neuropsychiatric side effects develop or if there is no clear clinical benefit after 4-6 weeks, as advised by the FDA 4
• The FDA has added a Boxed Warning for montelukast regarding neuropsychiatric events, which requires careful monitoring, as reported by the FDA 6
• Treatment response should be assessed after 4-6 weeks, and alternative therapy should be considered if no clear benefit is observed, as recommended by the National Asthma Education and Prevention Program 4 and the American Academy of Allergy, Asthma, and Immunology 5
• Patient selection factors favoring montelukast include poor inhaler technique or adherence issues with ICS, coexisting allergic rhinitis, exercise-induced bronchoconstriction, and aspirin-sensitive asthma, according to the American Academy of Allergy, Asthma, and Immunology 5
• Montelukast is not intended for rescue therapy during acute asthma exacerbations but rather as a daily controller medication, according to the American Academy of Pediatrics 6